Skip to content

Pharmacokinetic Study of Rezafungin in Patients with Suspected Intra-Abdominal Candidiasis: Peritoneal Diffusion and Candicidal Activity

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-521854-40-00
Acronym
REZAPACQ
Enrollment
20
Registered
2025-08-13
Start date
2025-12-22
Completion date
Unknown
Last updated
2025-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intra-Abdominal Candidiasis.

Brief summary

Peritoneal diffusion rate of Rezafungin. Ratio of Cmax, Cmin and Area Under the Rezafungin Curve in peritoneal fluid to Cmax, Cmin and Area Under the Rezafungin Curve in blood., Analysis of peritoneal fluid death curves in the samples per patient obtained according to the previous point.

Detailed description

Duration of treatment., Overall mortality, Attributable mortality., Clinical and microbiological cure.

Interventions

Sponsors

Fundacion Para La Investigacion Biomedica Del Hospital Universitario Ramon Y Cajal
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Design outcomes

Primary

MeasureTime frame
Peritoneal diffusion rate of Rezafungin. Ratio of Cmax, Cmin and Area Under the Rezafungin Curve in peritoneal fluid to Cmax, Cmin and Area Under the Rezafungin Curve in blood., Analysis of peritoneal fluid death curves in the samples per patient obtained according to the previous point.

Secondary

MeasureTime frame
Duration of treatment., Overall mortality, Attributable mortality., Clinical and microbiological cure.

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026